Claudia V. Perez Almeria, Omolade Otun, Roman R. Schlimgen, Thomas D Lamme, Lotte Di Niro, Caitrin Crudden, Jan Paul Bebelman, Noureldine Youssef, Lejla Musli, Shawn Jenjak, Vladimir Bobkov, Julia Drube, Carsten Hoffmann, Brian F. Volkman, Sébastien Granier, Chérine Bechara, Marco Siderius, Raimond Heukers, Christopher T. Schafer, Martine J. Smit
Stimulation of atypical chemokine receptor 3 (ACKR3) by chemokines does not activate G proteins but recruits arrestin. It is a chemokine scavenger that indirectly influences responses by restricting the availability of CXCL12, an agonist shared with the canonical receptor CXCR4. ACKR3 is upregulated in numerous disorders. Due to limited insights in chemokine-activated ACKR3 signaling, it is unclear how ACKR3 contributes to pathological phenotypes. One explanation may be that constitutive activity of ACKR3 drives non-canonical signaling through a basal receptor state. Here we characterize the constitutive responses of ACKR3 using inverse agonistic nanobodies to suppress its basal activity. These tools promote an inactive receptor conformation which decreased arrestin engagement and inhibited constitutive internalization. Basal non-chemotactic, cancer cell motility was also suppressed, suggesting a role for ACKR3 in this process. The basal receptor activity in pathophysiology may provide an alternate therapeutic approach for targeting ACKR3.